1584647-27-7

Basic information

• Product Name: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide
• Synonyms: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide
• CAS NO: 1584647-27-7
• Molecular Weight: 574.498
• Mol File: 1584647-27-7.mol

Chemical Properties

• Boiling Point: 714.9±60.0 °C(Predicted)
• Density: 1.44±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide(1584647-27-7)
• EPA Substance Registry System: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide(1584647-27-7)

Safety Data

• Hazardous Substances Data: 1584647-27-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide is used as a potential therapeutic agent for the development of new psychoactive drugs. Its unique structure and pharmacological properties make it a candidate for the treatment of various neurological and psychiatric disorders, as well as other conditions that may benefit from its specific mode of action.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide serves as a valuable compound for studying the structure-activity relationships of benzodiazepine-based drugs. Its unique features can provide insights into the design and synthesis of novel therapeutic agents with improved efficacy and reduced side effects.
Used in Drug Development:
(2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide is used as a lead compound in drug development. Its specific arrangement of functional groups and chiral centers can guide the optimization of drug candidates, potentially leading to the discovery of new medications with enhanced therapeutic profiles.

Upstream product

• 1584139-96-7 (S)-3-amino-5-(3-fluorophenyl)-9-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1584632-62-1 (S)-benzyl (5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
• 1584648-36-1 (2S,3R)-tert-butyl 6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1584648-37-2 (2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1584632-66-5 benzyl (5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
• 1401067-03-5 (2R,3S)-3-(tert-butoxycarbonyl)-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 407-62-5 5,5,5-trifluoropentanoic acid 
• 1401065-46-0 (4S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one 
• 1401067-07-9 tert-butyl (3R)-3-(((4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl)carbonyl)-6,6,6-trifluorohexanoate 
• 1401067-08-0 (R)-2-(2-(tert-butoxy)-2-oxoethyl)-5,5,5-trifluoropentanoic acid 
• 1401067-09-1 (2R,3S)-1-benzyl 4-tert-butyl 2,3-bis(3,3,3-trifluoropropyl)succinate 
• 1049037-18-4 tert-butyl 5,5,5-trifluoropentanoate 

Downstream Products

• 1584647-90-4 tert-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate 
• 1584647-92-6 ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonooxy)phenyl)acetate 
• 1584648-50-9 ((S,Z)-3-((R)-2-((S)-1-amino-3-trifluoro-1-oxopropan-2-yl)-5,5,5-trifluoropentanamido)-2-oxo-5-(3-fluorophenyl)-9-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 2-(4-(di-tert-butoxyphosphoryloxy)phenyl)acetate 
• 1584648-51-0 (S)-((S)-3-((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanamido)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate 
• 1584647-91-5 methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate 
• 1584647-93-7 ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valyl-L-valinate 
• 1584648-52-1 (S)-((S)-3-((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanamido)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 
• 1584648-47-4 (R)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanamido)thio)propanoate 
• 1584648-48-5 (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanamido)thio)propanoate 
• 1584648-49-6 (2R,3S)-3-(trifluoropropyl)-N₁-((S,Z)-1-(methylthiomethyl)-2-oxo-5-(3-fluorophenyl)-9-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methyl-2-(3,3,3-trifluoropropyl)succinamide 

Relevant articles and documents

BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF

Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.